Thiogenesis Therapeutics Corp TTIPF:OTCPK

*Data is delayed | Exchange | USD
Last | undefined
0.00UNCH (UNCH)
52 week range
0.00 - 0.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.00
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-

Key Stats

  • Market Cap23.35M
  • Shares Out45.5M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.00
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-
  • Market Cap23.35M
  • Shares Out45.5M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.10
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Thiogenesis Therapeutics Corp

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the...
Christopher Starr Ph.D.
Independent Chairman of the Board
Patrice Rioux M.D., Ph.D.
Chief Executive Officer, Director
Brook Riggins
Chief Financial Officer, Company Secretary, Director
Address
4 King Street West, Suite 401
Toronto, ON
M5H 1B6
Canada